Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.

ABSTRACT:

Objective

To develop an evidence-based guideline assessing pharmacologic options for treating Huntington disease (HD) chorea.

Methods

We evaluated available evidence from a structured literature review performed through February 2011.

Results and recommendations

If HD chorea requires treatment, clinicians should prescribe tetrabenazine (up to 100 mg/day), amantadine (300-400 mg/day), or riluzole (200 mg/day) (Level B) for varying degrees of expected benefit. Occurrence of adverse events should be discussed and monitored, particularly depression/suicidality and parkinsonism with tetrabenazine and elevated liver enzymes with riluzole. Clinicians may also prescribe nabilone for modest decreases (1- to <2-point changes on the Unified Huntington's Disease Rating Scale [UHD

SUBMITTER: Armstrong MJ 

PROVIDER: S-EPMC3413759 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature